Chapter 34 Leukotrienes

Principles of Medical Biology

Volumn 8, Issue C, 1997, Pages 655-686

  Newcombe, David S ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 4243839653     PISSN: 15692582     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1569-2582(97)80059-1     Document Type: Article

References (162)

1. 4. Clin. Biochem. 23 (1990) 459-468
2. Fiore S., Brezinski M.E., Sheppard K.-A., and Serhan C.N. The lipoxin biosynthetic circuit and their actions with human neutrophils. In: Wong P.Y.-K., and Serhan C.N. (Eds). Cell-Cell Interactions in the Release of Inflammatory Mediators (1990), Plenum Press, New York 109-132
3. Fitzpatrick F.A., and Murphy R.C. Cytochrome P-450 metabolism of arachidonic acid: Formation and biological actions of "epoxygenase"-derived eicosanoids. Pharmacol. Rev. 40 (1989) 229-241
4. Holtzman M.J. Arachidonic acid metabolism. Implications of biological chemistry for lung function and disease. Am. Rev. Respir. Dis. 143 (1991) 188-203
5. Hong S.L. The release of arachidonic acid from cellular lipids. Prog. Allergy 44 (1988) 99-139
6. Lewis R.A., Austen K.F., and Soberman R.J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med. 323 (1990) 645-655
7. McGiff J.C. Cytochrome P-450 metabolism of arachidonic acid. Ann. Rev. Pharmacol. 31 (1991) 339-369
8. Needleman P., Turk J., Jakschik B.A., et al. Arachidonic acid metabolism. Ann. Rev. Biochem. 55 (1986) 69-102
9. Newcombe D.S. Leukotrienes: Regulation of biosynthesis, metabolism, and bioactivity. J. Clin. Pharmacol. 28 (1988) 530-549
10. Pace-Asciak C.R. Hepoxilins. Gen. Pharmacol. 24 (1993) 805-810
11. Henderson Jr. W.R. The role of leukotrienes in inflammation. Ann. Intern. Med. 121 (1994) 684-697
12. Samuelsson B. Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 220 (1983) 568-575
13. Samuelsson B., Dahlen S.-V., Lindgren J.A., et al. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science 237 (1987) 1171-1176
14. Samuelsson B., Haeggstrom J.Z., and Weterholm A. Leukotriene biosynthesis. Ann. N.Y. Acad. Sci. 629 (1991) 89-99
15. Austruy E., Jeanpiette C., Antignac C., et al. Physical and genetic mapping of the dipeptidase gene DPEP1 to 16q24.3. Genomics 15 (1993) 684-687
16. 2 via GTP-binding proteins: arachidonic acid and its metabolites as second messengers. TINS 11 (1988) 117-123
17. 2 enzymes. Proc. Natl. Acad. Sci. USA 91 (1994) 11060-11064
18. 4. Arch. Biochem. Biophys. 244 (1986) 486-491
19. Brezinski M.E., and Serhan C.N. Selective incorporation of (15S)-hydroxyeicosatetraenoic acid in phosphatidylinositol of human neutrophils: Agonist-induced deacylation and transformation of stored hydroxyeicosanoids. Proc. Natl. Acad. Sci. USA 78 (1990) 6248-6252
20. Capdevila J.H., Faclck J.R., and Estabrook R.W. Cytochrome P450 and the arachidonate cascade. FASEB J. 6 (1992) 731-736
21. 4-dipeptidase in human serum. Prost. Leuko. Essent. Fatty Acids 47 (1992) 301-305
22. 4 in human monomorphonuclear leukocytes. J. Lipid Med. 6 (1993) 15-22
23. Corey E.J., and Su W. Total synthesis of biologically active metabolites of arachidonic acid. The two 8-hydroxy-11, 12(S,S)-epoxyeicosa-5,14(Z)-trienoic acids. Tetrahedron Let. 25 (1984) 5119-5122
24. Depre M., Friedman B., Tanaka W., et al. Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans. Clin. Pharmacol. Ther. 53 (1993) 602-607
25. Funk C.D., Funk L.B., Fitzgerald G.A., and Samuelsson B. Characterization of human 12-lipoxygenase genes. Proc. Natl. Acad. Sci. USA 89 (1992) 3962-3966
26. 4 hydrolase: Structural and functional properties of the active center. J. Lipid Med. 6 (1993) 1-13
27. Izumi T., Minami M., Ohishi N., et al. Site-directed mutagenesis of leukotriene A4 hydrolase: Distinction of leukotriene A4 hydrolase and aminopeptidase activities. J. Lipid Med. 6 (1993) 53-58
28. Kinsella J.E. Dietary polyunsaturated fatty acids, eicosanoids and chronic disease. Bol. Asoc. Med. P. Rico 81 (1989) 325-327
29. Kuhn H., Thiele B.J., Ostareck-Lederer A., Stender H., et al. Bacterial expression, purification and partial characterization of recombinant rabbit reticulocyte 15-lipoxygenase. Biochim. Biophys. Acta 1168 (1993) 73-78
30. 4. Proc. Natl. Acad. Sci. USA 89 (1992) 11598-11602
31. 4. Biochem. J. 295 (1993) 393-397
32. Laniado-Schwartzman M., and Abraham N.G. The renal cytochrome P-450 arachidonic acid system. Pediatr. Nephrol. 6 (1992) 490-498
33. Lee T.H. Pharmacological modulation of leukotriene and platelet activating factor biosynthesis and activities by alternative dietary fatty acids. Clin. Exp. Allergy 19 (1989) 15-23
34. Lindgren J.A., Stenke L., Mansour M., et al. Formation and effects of leukotrienes and lipoxins in human bone marrow. J. Lipid Med. 6 (1993) 313-320
35. McDonald P.P., Pouliot M., and Borgeat P. Enhancement by GM-CSF of agonist-induced 5-lipoxygenase activation in human neutrophils involves protein synthesis and gene transcription. J. Lipid Med. 6 (1993) 59-67
36. McGiff J.C., and Carroll M.A. Cytochrome P450-dependent arachidonate metabolites: Biological activities. Adv. Prost. Thromb. Leuko. Res. 19 (1989) 34-41
37. Pace-Asciak C.R., and Nigam S. Hepoxilins modulate second messenger systems in the human neutrophil. In: Wong P.Y.-K., and Serhan C.N. (Eds). Cell-Cell Interactions in the Release of Inflammatory Mediators (1991), Plenum Press, New York 133-139
38. 3. Biochem. Biophys. Res. Commun. 197 (1993) 869-873
39. 4 synthase. Proc. Natl. Acad. Sci. USA 89 (1992) 11603-11606
40. Peplow P.V., and Mikhailidis D.P. Platelet-activating factor (PAF) and its relation to prostaglandins, leukotrienes and other aspects of arachidonate metabolism. Prost. Leuko. Essent. Fatty Acids 41 (1990) 71-82
41. Piomelli D. Arachidonic acid in cell signaling. Curr. Opin. Cell Biol. 5 (1993) 274-280
42. Rajpert-De Meyts E., Heisterkamp N., and Groffen J. Cloning and nucleotide sequence of human γ-glutamyl transpeptidase. Proc. Natl. Acad. Sci. USA 85 (1988) 8840-8844
43. Rouzer C.A., Shimizu T., and Samuelsson. On the nature of the 5-lipoxygenase reaction in human leukocytes: Characterization of a membrane-associated stimulatory factor. Proc. Natl. Acad. Sci. USA 82 (1985) 7505-7509
44. Satoh S., Kusunoki C., Konta Y., et al. Cloning and structural analysis of genomic DNA for human renal peptidase. Biochim. Biophys. Acta 1172 (1993) 181-183
45. Shimizu T. Enzymes functional in the syntheses of leukotrienes and related compounds. Int. J. Biochem. 20 (1988) 661-666
46. Sigal E. The molecular biology of mammalian arachidonic acid metabolism. Amer. J. Physiol. 260 (1991) L13-L28
47. 4 biosynthesis. Adv. Prost. Thromb. Leuko. Res. 19 (1989) 21-25
48. Toh H., Yokoyama C., Tanabe T., et al. Molecular evolution of cyclooxygenase and lipoxygenase. Prost. 44 (1992) 291-315
49. Vickers P.J., Adam M., Charleson S., et al. Amino acid residues of 5-lipoxygenase-activating protein critical for the binding of leukotriene biosynthesis inhibitors. J. Lipid Med. 6 (1993) 31-42
50. Walden Jr. T.R., and Kalinich J.F. Radioprotection by leukotrienes: Is there a receptor mechanism?. Pharmac. Ther. 39 (1988) 379-384
51. Wigren J., Hervertsson H., Tollbom O., and Hammarstrom S. Metabolism of 12(S)-hydroxy-5,8,10,14-eicosatetraenoic acid by kidney and liver peroxisomes. J. Lipid Res. 34 (1993) 625-631
52. Yamamoto S. Mammalian lipoxygenases: Molecular and catalytic properties. Prost. Leuko. Essent. Fatty Acids 35 (1989) 219-229
53. Aharony D., and Krell R.D. Pharmacology of peptide leukotriene receptor antagonists. Ann. N.Y. Acad. Sci. 629 (1991) 125-132
54. 4 and its analogs to human polymorphonuclear leukocyte membrane receptors. Prostaglandins 33 (1987) 855-867
55. 4 binding units in cultured bovine aortic endothelial cells. J. Immunol. 137 (1986) 1985-1992
56. 4 binding sites in guinea pig uterus and lung preparations. J. Pharmacol. Exp. Ther. 232 (1985) 80-87
57. 4. Biochem. Biophys. Res. Commun. 118 (1984) 20-26
58. Drazen J.M., Austen K.F., Lewis R.A., et al. Comparative airway and vascular activities of leukotriene C-1 and D in vivo and in vitro. Proc. Natl. Acad. Sci. USA 77 (1980) 4353-4358
59. 4: identification of a subset of high affinity receptors that transduces the chemotactic response. J. Exp. Med. 159 (1984) 1027-1041
60. Halushka P.V., Mais D.E., Mayeux P.R., and Morinelli T.A. Thromboxane, prostaglandin and leukotriene receptors. Ann. Rev. Pharmacol. Toxicol. 10 (1989) 213-239
61. Krell R.D., and Shaw A. Peptide leukotrienes. Current status of research. J. Med. Chem. 34 (1991) 1235-1242
62. 4 on a smooth muscle cell line. J. Clin. Invest. 72 (1983) 1516-1519
63. 4 to ileal segments and subcellular fractions of ileal smooth muscle cells. Proc. Natl. Acad. Sci. USA 81 (1984) 4529-4533
64. 4 receptors. Prostaglandins 33 (1987) 617-625
65. 4 receptors in adult and fetal human lung. Biochem. Pharmacol. 34 (1985) 4311-4317
66. 4 binding to human neutrophils. Prostaglandins 28 (1984) 837-849
67. 4 receptors: effects of mediations and guanine nucleotides. Eur. J. Pharmacol. 106 (1984) 241-253
68. 4 receptor. J. Immunol. 147 (1991) 3096-3103
69. 4 receptor in guinea pig lung. Proc. Natl. Acad. Sci. USA 80 (1983) 7415-7419
70. Salmon J.A., and Garland L.G. Leukotriene antagonists and inhibitors of leukotriene biosynthesis as potential therapeutic agents. Prog. Drug Res. 37 (1991) 9-91
71. Snyder D.W., and Fleisch J.H. Leukotriene receptor antagonists as potential therapeutic agents. Ann. Rev. Pharmacol. Toxicol. 29 (1989) 123-143
72. 4 binding protein in rat liver cytosol as glutathione-S-transferase. J. Biol. Chem. 261 (1986) 8540-8546
73. 3 upregulates 5-lipoxygenase metabolism and 5-lipoxygenase activating protein in peripheral blood monocytes as they differentiate into mature macrophages. J. Lipid Med. 6 (1993) 43-51
74. Denzlingler C., Tetzloff W., Gerhartz H.H., et al. Differential activation of the endogenous leukotriene biosynthesis by two different preparations of granulocyte-macrophage colony-stimulating factor in healthy volunteers. Blood 81 (1993) 2007-2013
75. Gallwitz W.E., Mundy G.R., Lee C.H., et al. 5-Lipoxygenase metabolites of arachidonic acid stimulate isolated osteoclasts to resorb calcified matrices. J. Biol. Chem. 268 (1993) 10087-10094
76. 4 induces hyperadhesiveness in human endothelial cells for neutrophils. Blood 82 (1993) 948-953
77. 3 is the endogenous lipid mediator opposing hypotonic swelling of intact human platelets. Proc. Natl. Acad. Sci. USA 90 (1993) 2589-2592
78. 4 on endothelin-1 and prostacyclin release by cultured vascular cells. Pharmacol. Res. 27 (1993) 281-285
79. 4. Inflammation 17 (1993) 371-382
80. 4: Interactions with granulocyte-macrophage colony-stimulating factor. Blood 81 (1993) 352-356
81. 4-binding site of an anti-cysteinylleukotriene monoclonal antibody. Eur. J. Biochem. 214 (1993) 83-90
82. 2. J. Clin. Invest. 91 (1993) 2118-2125
83. 4-induced phospholipase D activation and degranulation of human neutrophils. Biochem. Pharmacol. 46 (1993) 139-148
84. 4 and immunological parameters in rheumatoid synovial fluids. Inflammation 15 (1991) 497-503
85. Koshihara Y., Isono T., Oda H., Karube S., and Hayashi Y. measurement of sulfidopeptide leukotrienes and their metabolism in human synovial fluid of patients with rheumatoid arthritis. Prostaglandins Leukot. Essent. Fatty Acids 32 (1988) 113-119
86. 4 levels are elevated in patients with active systemic lupus erythematosus. J. Rheumatol. 19 (1992) 252-258
87. Aibara S., Mori M., and Tsukada W. Inhibitory effect of DS-4574 on leukotriene- or antigen-induced bronchoconstriction in guinea pigs. Int. Arch. Allergy Immunol. 100 (1993) 268-273
88. Arm J.P., and Lee T.H. Sulphidopeptide leukotrienes in asthma. Clin. Sci. 84 (1993) 501-510
89. Bernard G.R., Korley V., Chee P., Swindell B., Ford-Hutchinson A.W., and Tagari P. Persistent generation of peptido leukotrienes in patients with the adult respiratory syndrome. Am. Rev. Respir. Dis. 144 (1991) 263-267
90. Bigby T.D. Transcellular metabolism of leukotrienes in the lung. In: Wong P.Y.-K., and Serhan C.N. (Eds). Cell-Cell Interactions in the Release of Inflammatory Mediators (1991), Plenum Press, New York 235-250
91. Bisgaard H. Sulphidoleukotrienes in human allergic diseases. Dan. Med. Bull. 36 (1989) 142-159
92. Bruynzeel P.L.B., and Verhagen J. The possible role of particular leukotrienes in the allergen-induced late-phase asthmatic reaction. Clin. Exp. Allergy 19 Suppl. 1 (1989) 25-32
93. 4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am. Rev. Respir. Dis. 143 (1991) 1025-1029
94. Dahlen S.-E., Kumlin M., Bjorak T., et al. Lipoxins and other lipoxygenase products with relevance to inflammatory reactions in the lung. Ann. N.Y. Acad. Sci. 629 (1991) 262-273
95. 4 from the urine of patient with airway obstruction. Am. Rev. Respir. Dis. 146 (1992) 104-108
96. 4 in human platelets and respiratory tissue: Transcellular formation of lipoxins and leukotrienes. In: Wong P.Y.-K., and Serhan C.N. (Eds). Cell-Cell Interactions in the Release of Inflammatory Mediators (1991), Plenum Press, New York 281-288
97. Feldberg W., and Kellaway C.H. Liberation of histamine and formation of lysocithin-like substances by cobra venom. J. Physiol. 94 (1938) 187-226
98. Ferreri N.R., Howland W.C., Stevenson D.D., and Speigelberg H.L. Release of leukotrienes, prostaglandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reaction to aspirin. Am. Rev. Respir. Dis. 137 (1988) 847-854
99. Goldman G., Welbourn R., Klausner J.M., Kubzik L., Valeri C.R., Shepro D., et al. Mast cells and leukotrienes mediate neutrophil sequestration and lung edema after remote ischemia in rodents. Surgery 112 (1992) 578-586
100. Grimes D., Sturm R.J., Marinari L.R., et al. WY-50, 295 tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterization and antiallergic activity. Eur. J. Pharmacol. 236 (1993) 217-228
101. Holtzman R.B., and Hageman J.R. The role of lipid mediators in oxygen-induced lung injury. In: Wong P.Y.-K., and Serhan C.N. (Eds). Cell-Cell Interactions in the Release of Inflammatory Mediators (1991), Plenum Press, New York 241-268
102. Kellaway C.H., and Trethewie E.R. The liberation of a slow-reacting smooth muscle-stimulating substance in anaphylaxis. Q. J. Exp. Physiol. 30 (1940) 121-145
103. 4. Cancer 66 (1990) 2357-2364
104. Klein J., Trouwborst A.J., and Erdmann W. Role of arachidonic acid metabolites in pulmonary oxygen toxicity. In: Erdmann W., and Bruley D.F. (Eds). Oxygen Transport to Tissues XIV (1992), Plenum Press, New York 807-811
105. 4 is markedly elevated in epithelial lining fluid of patients with cystic fibrosis. Am. Rev. Respir. Dis. 48 (1993) 896-901
106. 4 and granulocytic infiltration into asthmatic airways. Lancet 341 (1993) 989-990
107. Naclerio R.M., Baroody F.M., and Togias A.G. The role of leukotrienes in allergic rhinitis: A review. Am. Rev. Respir. Dis. 143 (1991) S91-S95
108. 2 in BAL fluid after methacholine challenge in asthmatic subjects. Eur. Respir. J. 6 (1993) 405-412
109. Ortiz J.L., Labat C., Norel X., et al. Response to anti-human IgE in human pulmonary arteries. Regulation by endothelium. Am. Rev. Resp. Dis. 147 (1993) 1029-1033
110. Piper P.J. Leukotrienes and the airways. Eur. J. Anaesthes. 6 (1989) 241-255
111. Punnonen J., Punnonen K., Jansen C.T., et al. Interferon (IFN)-α, IFN-γ, interleukin (IL)-2, and arachidonic acid metabolites modulate IL-4-induced IgE synthesis similarly in healthy persons and in atopic dermatitis patients. Allergy 48 (1993) 189-195
112. Sampson A.P., Spencer D.A., Green C.P., Piper P.J., and Price J.F. Leukotrienes in the sputum and urine of cystic fibrosis children. Br. J. Clin. Pharmacol. 30 (1990) 861-869
113. Sladek K., and Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur. Respir. J. 6 (1993) 391-399
114. 4 in humans. Effect of indomethacin. Am. Rev. Respir. Dis. 141 (1990) 1441-1445
115. Spencer D.A., Sampson A.P., Green C.P., Costello J.F., Piper P.J., and Price J.F. Sputum cysteinyl-leukotriene levels correlate with the severity of pulmonary disease in children with cystic fibrosis. Pediatr. Pulmonol. 12 (1992) 90-94
116. Su M., Chi E.Y., Bishop M.J., and Henderson Jr. W.R. Lung mast cells increase in number and degranulate during pulmonary artery occlusion/reperfusion injury in dogs. Am. Rev. Respir. Dis. 147 (1993) 448-456
117. 4: Self-limitations of the priming response with protein synthesis. Am. J. Resp. Cell Mol. Biol. 8 (1993) 500-508
118. Wegner C.D., Gundel R.H., Abraham W.M., et al. The role of 5-lipoxygenase products in preclinical models of asthma. J. Allergy Clin. Immunol. 91 (1993) 917-929
119. 4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. Am. Rev. Respir. Dis. 142 (1990) 112-119
120. Wenzel S.E., Wescott J.Y., and Larsen G.L. Bronchoalveolar lavage fluid mediator levels 5 minutes after allergen challenge in atopic subjects with asthma: Relationship to the development of late asthmatic responses. J. Allergy Clin. Immunol. 87 (1991) 540-548
121. Belch J.J.F. Eicosanoids and rheumatology: Inflammatory and vascular aspects. Prost. Leuko. Essent. Fatty Acids 36 (1989) 219-234
122. 4 transcriptionally activates interleukin-6 expression involving NK-κB and NF-IL6. Eur. J. Immunol. 22 (1992) 2705-2711
123. 4 in the immune system. Int. J. Immunopharmac. 14 (1992) 441-449
124. Goldyne M.E. Lymphocytes and arachidonic acid metabolism. Prog. Allergy 44 (1998) 140-152
125. Gulbins E., Siow Y., and Vitale G.C. Complement 5a induces in vivo synthesis of cysteinyl leukotrienes in rats. Prost. Leuko. Essent. Fatty Acids 48 (1993) 331-334
126. Johnson H.M., Russell J.K., and Torres B.A. Second messenger role of arachidonic acid and its metabolites in interferon-gamma production. J. Immunol. 137 (1986) 3053-3056
127. Rola-Pleszczynski M. Leukotrienes and the immune system. J. Lipid Med. 1 (1989) 149-159
128. 4 and PAF in the cytokine network. In: Wong P.Y.-K., and Serhan C.N. (Eds). Cell-Cell Interactions in the Release of Inflammatory Mediators (1991), Plenum Press, New York 205-221
129. Fauler J., and Frolich J.C. Cardiovascular effects of leukotrienes. Cardiovasc. Drugs Ther. 3 (1989) 499-505
130. Fiedler V.B. Role of arachidonic acid metabolites in cardiac ischemia and reperfusion injury. Pharmacother. 8 (1988) 158-168
131. 4 receptor antagonist, L-648,051, and a dual inhibitor lipoxygenase and cyclooxygenase, BQ-755C, on digoxin-induced arrhythmias in guinea-pigs. Arch. Int. Pharmacodyn. 321 (1993) 72-80
132. 4 produced in myocardium impair coronary flow and ventricular function after two hours of global ischaemia in rat heart. Cardiovasc. Res. 27 (1993) 770-773
133. McGiff J.C., and Laniado-Schwatzman M. Arachidonic acid metabolites and blood pressure control. Clin. Physiol. Biochem. 6 (1988) 179-187
134. Piper P.J., Stanton A.W.B., Yaacob H.B., and Antoniw J. Leukotrienes in the cardiovascular system. Biochem. Soc. Trans. 16 (1988) 482-483
135. Ardaillou R., Baud L., and Sraer J. Leukotrienes and reactive oxygen species as mediators of glomerular injury. Am. J. Nephrol. 9 Suppl. 1 (1989) 17-22
136. Badr K.F. Cell-cell interactions in the regulation of glomerular inflammation by arachidonate lipoxygenase products. In: Wong P.Y.-K., and Serhan C.N. (Eds). Cell-Cell Interactions in the Release of Inflammatory Mediators (1991), Plenum Press, New York 335-346
137. Badr K.F. 15-Lipoxygenase products as leukotriene antagonists: Therapeutic potential in glomerulonephritis. Kid. Intl. 24 Suppl. 38 (1992) S
138. Bresnahan B.A., Wu S., Fenoy F.J., Roman R.J., and Lianos E.A. Mesangial cell immune injury. Hemodynamic role of leukocyte- and platelet-derived eicosanoids. J. Clin. Invest. 90 (1992) 2304-2312
139. Hartupee D.A., Passmore J.C., and Jimenez A. Effect of leukotrienes of renal water excretion. Prost. Leuko. Essent. Fatty Acids 48 (1993) 297-303
140. 4 is a mediator of proteinuria and glomerular hemodynamic abnormalities in passive Heymann nephritis. J. Clin. Invest. 91 (1993) 1507-1515
141. Takahashi K., and Badr K.F. Lipoxygenase products as mediators in immune-mediated glomerular injury. Sem. Nephrol. 13 (1993) 129-136
142. Wardle E.N. Phospholipid derived mediators and glomerulonephritis. Med. Inflamm. 2 (1993) 99-102
143. Boughton N.K., and Whittle J.R. The role of leukotrienes in the pathogenesis of gastric ulceration. Pharmacol. Res. Commun. 20 (1988) 919-934
144. Hawkey C.J., Mahida Y.R., and Hawthorne A.B. Therapeutic interventions in gastrointestinal disease based on an understanding of inflammatory mediators. Agents Actions, Special Conference Issue (1992) C22-C26
145. 4 synthesis in vitro in inflammatory bowel disease: inhibition by the selective 5-lipoxygenase inhibitor BWA4C. Gut 33 (1992) 513-517
146. 4 synthesis in patients taking non-steroidal anti-inflammatory drugs. Gut 34 (1993) 742-747
147. Kaminski D.L. Arachidonic acid metabolites in hepatobiliary physiology and disease. Gastroenterol. 97 (1989) 781-792
148. Kennedy N.P., and Keeling P.W.N. Review: lipoxygenase inhibitors and the gut. Aliment. Pharmacol. Therap. 1 (1987) 263-272
149. Keppler D., Huber M., and Baumert T. Leukotrienes as mediators in disease of the liver. Sem. Liver Dis. 8 (1988) 357-366
150. 4, levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 91 (1986) 837-844
151. Lauritsen K., Laursen L.S., Bukhave K., and Rask-Madsen J. In vivo profiles of eicosanoids in ulcerative colitis, Crohn's disease, and Clostridium difficile colitis. Gastroenterology 95 (1988) 11-17
152. Smith D.L. Effects of the neuroimmune mediators, peptidoleukotrienes, endothelin, and interleukin-1 on intestinal ion transport. Ann. N.Y. Acad. Sci. 664 (1992) 260-274
153. 4, and platelet-activating factor receptor sites in the brain. Ann. N.Y. Acad. Sci. 664 (1992) 100-111
154. 4 produces hyperalgesia that is dependent on polymorphonuclear leukocytes. Science 225 (1984) 743-745
155. Ojeda S.R., Urbanski H.F., Junier M.-P., and Capdevila J. The role of arachidonic acid and its metabolites in the release of neuropeptides. Ann. N.Y. Acad. Sci. 664 (1992) 192-207
156. Siesjo B.K., Agardh C.-D., Bengtsson F., and Smith M.-L. Arachidonic acid metabolism in seizures. Ann. N.Y. Acad. Sci. 664 (1992) 323-339
157. Alanko J., Riutta A., and Vapaatoalo H. Effects of catecholamines on eicosanoid synthesis with special reference to prostanoid/leukotriene ratio. Free Rad. Biol. 13 (1992) 677-688
158. Eberhardt I., and Kiesel L. Role of arachidonic acid and lipoxygenase products in the mechanism of gonadotropin secretion: An update. Prost. Leuko. Essent. Fatty Acids 47 (1992) 239-246
159. Dowd P.M., and Greaves M.W. Cutaneous responses to lipoxygenase products of arachidonic acid. Acta Derm. Venereol. Suppl. (Stockholm) 120 (1985) 18-22
160. Fauler J., Neumann C., Tsikas D., and Frolich J. Enhanced synthesis of cysteinyl leukotrienes in psoriasis. J. Invest. Dermatol. 99 (1992) 8-11
161. 4 but not 12-hydroxy-eicosatetraenoic acid, is present in biologically/active amounts in acute guttate lesions. J. Invest. Dermatol. 92 (1989) 837-841
162. 4 and platelet-activating in human skin. Arch. Dermatol. 284 Suppl. (1992) S12-S17